CA2746746C - Arylcyclopropylacetamide derivatives useful as glucokinase activators - Google Patents

Arylcyclopropylacetamide derivatives useful as glucokinase activators Download PDF

Info

Publication number
CA2746746C
CA2746746C CA2746746A CA2746746A CA2746746C CA 2746746 C CA2746746 C CA 2746746C CA 2746746 A CA2746746 A CA 2746746A CA 2746746 A CA2746746 A CA 2746746A CA 2746746 C CA2746746 C CA 2746746C
Authority
CA
Canada
Prior art keywords
compound
solution
glucose
pharmaceutically acceptable
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2746746A
Other languages
English (en)
French (fr)
Other versions
CA2746746A1 (en
Inventor
Ana Belen Bueno Melendo
Francisco Javier Agejas-Chicharro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2746746A1 publication Critical patent/CA2746746A1/en
Application granted granted Critical
Publication of CA2746746C publication Critical patent/CA2746746C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2746746A 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators Active CA2746746C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380341.1 2008-12-19
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19
US61/153,781 2009-02-19
PCT/US2009/067603 WO2010080333A1 (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Publications (2)

Publication Number Publication Date
CA2746746A1 CA2746746A1 (en) 2010-07-15
CA2746746C true CA2746746C (en) 2013-09-24

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2746746A Active CA2746746C (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Country Status (34)

Country Link
US (1) US8063079B2 (https=)
EP (1) EP2379517B1 (https=)
JP (1) JP5497064B2 (https=)
KR (1) KR101290437B1 (https=)
CN (1) CN102256952B (https=)
AR (1) AR074470A1 (https=)
AU (1) AU2009335931B2 (https=)
BR (1) BRPI0923183B1 (https=)
CA (1) CA2746746C (https=)
CO (1) CO6382120A2 (https=)
CR (1) CR20110342A (https=)
DK (1) DK2379517T3 (https=)
DO (1) DOP2011000197A (https=)
EA (1) EA019055B1 (https=)
EC (1) ECSP11011150A (https=)
ES (1) ES2435242T3 (https=)
HR (1) HRP20130983T1 (https=)
IL (1) IL213210A (https=)
JO (1) JO2979B1 (https=)
MA (1) MA32902B1 (https=)
MX (1) MX2011006434A (https=)
MY (1) MY180567A (https=)
NZ (1) NZ592930A (https=)
PA (1) PA8851901A1 (https=)
PE (1) PE20120339A1 (https=)
PL (1) PL2379517T3 (https=)
PT (1) PT2379517E (https=)
SG (1) SG172256A1 (https=)
SI (1) SI2379517T1 (https=)
TN (1) TN2011000294A1 (https=)
TW (1) TWI395748B (https=)
UA (1) UA104742C2 (https=)
WO (1) WO2010080333A1 (https=)
ZA (1) ZA201103944B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
CN105899192B (zh) 2013-11-22 2019-08-13 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010745A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
DE60336850D1 (en) 2003-01-06 2011-06-01 Lilly Co Eli Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7432287B2 (en) * 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
KR100890695B1 (ko) 2004-08-12 2009-03-26 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
EP1824835A1 (en) * 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
RU2008103142A (ru) * 2005-07-01 2009-08-10 Новартис АГ (CH) Комбинация органических соединений
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
WO2007051845A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
WO2007051846A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
KR20090025358A (ko) * 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 글루코키나제 활성화제로서의 피라졸
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체

Also Published As

Publication number Publication date
JO2979B1 (en) 2016-03-15
BRPI0923183B1 (pt) 2019-03-19
IL213210A (en) 2015-03-31
BRPI0923183A2 (pt) 2016-02-16
AR074470A1 (es) 2011-01-19
ZA201103944B (en) 2012-11-28
AU2009335931B2 (en) 2012-05-31
JP5497064B2 (ja) 2014-05-21
WO2010080333A1 (en) 2010-07-15
DOP2011000197A (es) 2011-09-15
JP2012512874A (ja) 2012-06-07
ES2435242T3 (es) 2013-12-17
BRPI0923183A8 (pt) 2017-09-12
IL213210A0 (en) 2011-07-31
TN2011000294A1 (en) 2012-12-17
US8063079B2 (en) 2011-11-22
EP2379517B1 (en) 2013-08-28
PA8851901A1 (es) 2010-07-27
TWI395748B (zh) 2013-05-11
PL2379517T3 (pl) 2014-01-31
MA32902B1 (fr) 2011-12-01
CN102256952A (zh) 2011-11-23
SI2379517T1 (sl) 2013-10-30
SG172256A1 (en) 2011-07-28
CN102256952B (zh) 2013-12-11
TW201029999A (en) 2010-08-16
KR101290437B1 (ko) 2013-07-29
NZ592930A (en) 2013-01-25
DK2379517T3 (da) 2013-09-30
CO6382120A2 (es) 2012-02-15
KR20110086751A (ko) 2011-07-29
HRP20130983T1 (hr) 2013-11-22
PT2379517E (pt) 2013-11-21
MY180567A (en) 2020-12-02
EA019055B1 (ru) 2013-12-30
EA201170845A1 (ru) 2011-12-30
US20100160395A1 (en) 2010-06-24
AU2009335931A1 (en) 2011-07-07
CA2746746A1 (en) 2010-07-15
ECSP11011150A (es) 2011-07-29
PE20120339A1 (es) 2012-04-16
EP2379517A1 (en) 2011-10-26
UA104742C2 (uk) 2014-03-11
CR20110342A (es) 2011-09-14
MX2011006434A (es) 2011-07-19

Similar Documents

Publication Publication Date Title
CA2904985C (en) Pyrazole-amide compound and medicinal uses therefor
EP2297120B1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
US20150018403A1 (en) Fluorene-amide compounds and pharmaceutical use thereof
CA2746746C (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
KR102730711B1 (ko) 피리미딘-5-카르복스아미드 화합물
HK1159635A (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
HK1159635B (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
HK40070623A (en) Pyrimidine-5-carboxamide compound
HK40070623B (zh) 嘧啶-5-甲酰胺化合物

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124